Abstract:Background and objectives: Up to 46% of patients with presumed autoimmune limbic encephalitis are seronegative for all currently known central nervous system (CNS) antigens. We developed a cell-based assay (CBA) to screen for novel neural antibodies in serum and cerebrospinal fluid (CSF) using neurons and astrocytes derived from human-induced pluripotent stem cells (hiPSCs). Methods: Human iPSC-derived astrocytes or neurons were incubated with serum/CSF from 99 patients [42 with inflammatory neurological diseases (IND) and 57 with non-IND (NIND)]. The IND group included 11 patients with previously established neural antibodies, six with seronegative neuromyelitis optica spectrum disorder (NMOSD), 12 with suspected autoimmune encephalitis/paraneoplastic syndrome (AIE/PNS), and 13 with other IND (OIND). IgG binding to fixed CNS cells was detected using fluorescently-labeled antibodies and analyzed through automated fluorescence measures. IgG neuronal/astrocyte reactivity was further analyzed by flow cytometry. Peripheral blood mononuclear cells (PBMCs) were used as CNS-irrelevant control target cells. Reactivity profile was defined as positive using a Robust regression and Outlier removal test with a false discovery rate at 10% following each individual readout. Results: Using our CBA, we detected antibodies recognizing hiPSC-derived neural cells in 19/99 subjects. Antibodies bound specifically to astrocytes in nine cases, to neurons in eight cases, and to both cell types in two cases, as confirmed by microscopy single-cell analyses. Highlighting the significance of our comprehensive 96-well CBA assay, neural-specific antibody binding was more frequent in IND (15 of 42) than in NIND patients (4 of 57) (Fisher's exact test, p = 0.0005). Two of four AQP4+ NMO and four of seven definite AIE/PNS with intracellular-reactive antibodies [1 GFAP astrocytopathy, 2 Hu+, 1 Ri+ AIE/PNS)], as identified in diagnostic laboratories, were also positive with our CBA. Most interestingly, we showed antibody-reactivity in two of six seronegative NMOSD, six of 12 probable AIE/PNS, and one of 13 OIND. Flow cytometry using hiPSC-derived CNS cells or PBMC-detected antibody binding in 13 versus zero patients, respectively, establishing the specificity of the detected antibodies for neural tissue. Conclusion: Our unique hiPSC-based CBA allows for the testing of novel neuron-/astrocyte-reactive antibodies in patients with suspected immune-mediated neurological syndromes, and negative testing in established routine laboratories, opening new perspectives in establishing a diagnosis of such complex diseases.

Human-derived monoclonal autoantibodies as interrogators of cellular proteotypes in the brain

Antibodies in neurological diseases: Established, emerging, explorative

Autoimmune central nervous system disorders: Antibody testing and its clinical utility

Learnings about Aβ from Human Brain Recommend the Use of a Live-Neuron Bioassay for the Discovery of Next Generation Alzheimer’s Disease Immunotherapeutics

Human stem cell-derived neurons and astrocytes to detect novel auto-reactive IgG response in immune-mediated neurological diseases

Epitope landscape in autoimmune neurological disease and beyond

Editorial: Antibody-Mediated Autoimmune Diseases of the CNS: Challenges and Approaches to Diagnosis and Management

Unveiling the Autoreactome: Proteome-wide Immunological Fingerprints Reveal the Promise of Plasma Cell Depleting Therapy.

Predicting the future of autoimmune encephalitides

Monoclonal Antibodies as Neurological Therapeutics

Classical Complement Pathway Inhibition in a "Human-On-A-Chip" Model of Autoimmune Demyelinating Neuropathies

Unveiling the Proteome-Wide Autoreactome Enables Enhanced Evaluation of Emerging CAR T Cell Therapies in Autoimmunity

A Human Brain-Chip for modelling brain pathologies and screening of BBB crossing therapeutic strategies

HDAC Inhibitors recapitulate Human Disease-Associated Microglia Signatures in vitro

Turncoat antibodies unmasked in a model of autoimmune demyelination: from biology to therapy

Human Autoantibodies against the AMPA Receptor Subunit GluA2 Induce Receptor Reorganization and Memory Dysfunction

A Human Brain-Chip for Modeling Brain Pathologies and Screening Blood–Brain Barrier Crossing Therapeutic Strategies

An in Vitro Paradigm to Assess Potential Anti-Aβ Antibodies for Alzheimer’s Disease

Immunoproteomics technologies in the discovery of autoantigens in autoimmune diseases

Autoantibody profiling of monoamine oxidase A knockout mice, an autism spectrum disorder model

Recovery of a human natural antibody against the noncollagenous-1 domain of type IV collagen using humanized models